Medtronic Inc. (MDT) recently reported the first enrollment for its Attain Success trial. The trial evaluates implant success, complication rates and procedure times for the company’s Attain Family of left-heart leads and delivery systems portfolio which are already available in the market.
The Attain Success trial enrollment will have roughly 2,000 patients at 150 medical centers in 18 countries around the world. The company will analyze data at baseline, implant and three months post-implant. The study will also capture implant success and complication rates (up to three months), procedure times, handling feedback and physician survey data.
In addition, the Attain Success trial enrollment will have a sub-study that will assess final left-heart lead placement site. Patients enrolled in the test will have a cardiac resynchronization therapy-defibrillator (CRT) device implanted in them. Results from the test are expected in 30 months.
If successful, the Attain Success trial will give physicians an alternative treatment option for patients with difficult-to-navigate anatomies. This will in turn boost Medtronic’s top-line.
Medtronic is one of the world’s leading medical technology companies, specializing in implantable and interventional therapy devices and products. The company’s main competitors include St. Jude Medical (STJ) and Boston Scientific Corporation (BSX). Medtronic’s management has a typical ‘ONE Medtronic’ approach that encompasses the following goals: drive sustainable long-term growth of 9%−11% through innovation; focus on operating margins − increase by 300 to 400 basis points; grow EPS by 11%−14% and return a minimum of 40%−50% of free cash flow to shareholders annually; and align the organization for consistent execution. Medtronic’s first quarter of fiscal 2010 results indicate that the company is well on track in achieving these goals.
Read the full analyst report on “MDT”
Read the full analyst report on “STJ”
Read the full analyst report on “BSX”
Zacks Investment Research
